Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (317) 317
breast cancer (301) 301
oncology (301) 301
index medicus (299) 299
female (291) 291
breast neoplasms - drug therapy (219) 219
postmenopausal women (170) 170
cancer (152) 152
chemotherapy (149) 149
endocrine therapy (135) 135
breast neoplasms - pathology (123) 123
care and treatment (117) 117
double-blind (109) 109
metastasis (99) 99
everolimus plus exemestane (89) 89
antineoplastic agents - therapeutic use (87) 87
aromatase inhibitors (78) 78
pharmacology & pharmacy (73) 73
randomized-trial (73) 73
tamoxifen (71) 71
breast neoplasms - metabolism (69) 69
medicine & public health (68) 68
treatment outcome (66) 66
1st-line treatment (63) 63
antineoplastic agents, hormonal - therapeutic use (61) 61
aged (60) 60
health aspects (60) 60
hematology, oncology and palliative medicine (60) 60
antineoplastic combined chemotherapy protocols - therapeutic use (59) 59
phase-ii trial (59) 59
trastuzumab (59) 59
drug therapy (57) 57
middle aged (57) 57
estrogen (56) 56
metastatic breast cancer (55) 55
open-label (54) 54
clinical trials (53) 53
research (53) 53
phase-iii trial (52) 52
review (52) 52
everolimus (51) 51
aromatase inhibitors - therapeutic use (50) 50
cancer therapies (48) 48
analysis (47) 47
clinical trials as topic (46) 46
neoplasm metastasis (46) 46
receptor, erbb-2 - metabolism (45) 45
estrogen-receptor (42) 42
therapy (42) 42
adult (41) 41
breast neoplasms - genetics (41) 41
breast neoplasms - therapy (41) 41
adjuvant chemotherapy (39) 39
fulvestrant (38) 38
chemotherapy, adjuvant (37) 37
disease-free survival (37) 37
molecular targeted therapy (37) 37
receptors, estrogen - metabolism (37) 37
women (37) 37
letrozole (36) 36
plus (36) 36
randomized phase-ii (36) 36
premenopausal women (35) 35
first-line therapy (34) 34
prognosis (34) 34
tumors (34) 34
estrogen plus progestin (33) 33
plus zoledronic acid (33) 33
combination (32) 32
obstetrics & gynecology (32) 32
tamoxifen - therapeutic use (32) 32
anastrozole (31) 31
breast neoplasms - mortality (31) 31
drug resistance, neoplasm (31) 31
phase-iii (31) 31
randomized controlled trials as topic (31) 31
trial (31) 31
aromatase inhibitor (30) 30
growth-factor receptor (30) 30
postmenopause (30) 30
progression-free survival (30) 30
survival (30) 30
antineoplastic agents (29) 29
plus exemestane (29) 29
quality of life (29) 29
quality-of-life (29) 29
follow-up (28) 28
adjuvant treatment (27) 27
animals (27) 27
antineoplastic agents - pharmacology (27) 27
development and progression (27) 27
surgical adjuvant breast (27) 27
antineoplastic agents - adverse effects (26) 26
internal medicine (26) 26
medicine, general & internal (26) 26
neoplasm staging (26) 26
targeted therapy (26) 26
aged, 80 and over (25) 25
article (25) 25
fulvestrant 500 mg (25) 25
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Unravelling exemestane: From biology to clinical prospects
by Sobral, Ana Filipa and Amaral, Cristina and Correia-da-Silva, Georgina and Teixeira, Natércia
Journal of Steroid Biochemistry and Molecular Biology, ISSN 0960-0760, 10/2016, Volume 163, pp. 1 - 11
Aromatase inhibitors (AIs) are anti-tumor agents used in clinic to treat hormone-dependent breast cancer. AIs block estrogens biosynthesis by inhibiting the... 
Endocrine therapy | Clinical trials | Endocrine resistance | Hormone-dependent breast cancer | Exemestane | Aromatase inhibitors | CONTROLLED-TRIAL | BONE-MINERAL DENSITY | BIOCHEMISTRY & MOLECULAR BIOLOGY | DOWN-REGULATION | ESTROGEN-RECEPTOR | POSITIVE BREAST-CANCER | EVEROLIMUS PLUS EXEMESTANE | NONSTEROIDAL AROMATASE INHIBITOR | RANDOMIZED PHASE-II | ENDOCRINOLOGY & METABOLISM | POSTMENOPAUSAL WOMEN | Anastrozole | Apoptosis - drug effects | Humans | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Breast Neoplasms - drug therapy | Autophagy - drug effects | Breast Neoplasms - metabolism | Breast Neoplasms - pathology | Cell Cycle Checkpoints - drug effects | Biotransformation | Tamoxifen - therapeutic use | Cell Line, Tumor | Female | Androstadienes - therapeutic use | Androstadienes - metabolism | Aromatase Inhibitors - therapeutic use | Nitriles - therapeutic use | Triazoles - therapeutic use | Metabolites | Oncology, Experimental | Estrogen | Cytochrome P-450 | Postmenopausal women | Research | Antineoplastic agents | Sulfates | Density | Antimitotic agents | Dehydroepiandrosterone | Epidermal growth factor | Cell death | Bones | Mitogens | Protein kinases | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Triggering of suicidal erythrocyte death by exemestane
by Al Mamun Bhuyan, Abdulla and Bissinger, Rosi and Cao, Hang and Lang, Florian
Cellular Physiology and Biochemistry, ISSN 1015-8987, 06/2017, Volume 42, Issue 1, pp. 1 - 12
Background/Aims: The steroidal aromatase inactivator exemestane blocks estrogen biosynthesis and is thus employed for the prevention and treatment of breast... 
Eryptosis | Oxidative stress | Calcium | Phosphatidylserine | ERYPTOSIS FOLLOWING EXPOSURE | PHYSIOLOGY | ADVANCED BREAST-CANCER | STIMULATION | CELL BIOLOGY | EVEROLIMUS PLUS EXEMESTANE | PHASE-II TRIAL | IN-VITRO | PHOSPHATIDYLSERINE EXPOSURE | POSTMENOPAUSAL WOMEN | AROMATASE INHIBITORS | Immunoassay | Reactive Oxygen Species - metabolism | Calcium - metabolism | Phosphatidylserines - pharmacology | Xanthenes - chemistry | Cell Size - drug effects | Humans | Cells, Cultured | Ceramides - analysis | Imidazoles - pharmacology | Calcium - chemistry | Erythrocytes - drug effects | Flow Cytometry | Androstadienes - pharmacology | Acetylcysteine - pharmacology | Erythrocytes - metabolism | Erythrocytes - cytology | Pyridines - pharmacology | Aniline Compounds - chemistry | Oxidative Stress - drug effects | Eryptosis - drug effects | Breast cancer | Kinases | Anemia | Erythrocytes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Aromatase inhibitors in the breast cancer clinic: Focus on exemestane
by Van Asten, Kathleen and Neven, Patrick and Lintermans, Anneleen and Wildiers, Hans and Paridaens, Robert
Endocrine-Related Cancer, ISSN 1351-0088, 02/2014, Volume 21, Issue 1, pp. R31 - R49
Breast cancer is the most prevalent type of cancer in women and responsible for significant female cancer-related mortality worldwide. In the Western world,... 
BONE-MINERAL DENSITY | ONCOLOGY | RANDOMIZED PHASE-II | ADJUVANT ENDOCRINE THERAPY | ENDOCRINOLOGY & METABOLISM | TERM-FOLLOW-UP | PLACEBO-CONTROLLED TRIAL | QUALITY-OF-LIFE | POSTMENOPAUSAL WOMEN | PLUS ZOLEDRONIC ACID | 3RD-LINE HORMONAL TREATMENT | FIRST-LINE THERAPY | Aromatase Inhibitors - adverse effects | Breast Neoplasms - enzymology | Humans | Female | Androstadienes - therapeutic use | Chemotherapy, Adjuvant | Androstadienes - adverse effects | Aromatase Inhibitors - therapeutic use | Breast Neoplasms - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer
by Per E. Lønning and Jürgen Geisler and Lars E. Krag and Bjørn Erikstein and Yngve Bremnes and Anne I. Hagen and Ellen Schlichting and Ernst A. Lien and Erik S. Øfjord and Jolanda Paolini and Anna Polli and Giorgio Massimini
Journal of Clinical Oncology, ISSN 0732-183X, 08/2005, Volume 23, Issue 22, pp. 5126 - 5137
Purpose To evaluate potential detrimental effects of exemestane on bone and lipid metabolism. Patients and Methods Postmenopausal women with early breast... 
RISK-FACTORS | ONCOLOGY | BIOCHEMICAL MARKERS | RANDOMIZED CONTROLLED-TRIAL | HORMONE REPLACEMENT THERAPY | ESTROGEN PLUS PROGESTIN | CORONARY-HEART-DISEASE | POSTMENOPAUSAL WOMEN | 1ST-LINE THERAPY | STEROIDAL AROMATASE INHIBITOR | TAMOXIFEN THERAPY | Aromatase Inhibitors - administration & dosage | Breast Neoplasms - surgery | Bone Resorption | Double-Blind Method | Humans | Middle Aged | Breast Neoplasms - drug therapy | Aromatase Inhibitors - adverse effects | Bone Density - drug effects | Androstadienes - administration & dosage | Lipids - blood | Placebos | Postmenopause | Female | Aged | Androstadienes - therapeutic use | Androstadienes - adverse effects | Aromatase Inhibitors - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane
by Willemsen, A.E.C.A.B and Geus-Oei, L.F. de and Boer, Maaike de and Tol, Jolien and Kamm, Yvonne and Jong, P.C. de and Jonker, M.A and Aarntzen, E.H.J.G and Gerritsen, W.R and Herpen, C.M.L. van and Erp, N.P. van
Targeted Oncology, ISSN 1776-2596, 2018, Volume 13, Issue 5, pp. 641 - 648
Background Treating breast cancer patients with everolimus and exemestane can be challenging due to toxicity and suboptimal treatment responses. Objective We... 
MAMMALIAN TARGET | PLUS EXEMESTANE | SOLID TUMORS | EFFICACY | ONCOLOGY | MTOR INHIBITOR EVEROLIMUS | SAFETY | PHASE-I | ENDOCRINE MONOTHERAPY | PET | CHEMOTHERAPY | Cancer patients | Care and treatment | Patient outcomes | Breast cancer | Angiogenesis inhibitors | Drug therapy | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane
by Willemsen, Annelieke E. C. A. B and de Geus-Oei, Lioe-Fee and de Boer, Maaike and Tol, Jolien and Kamm, Yvonne and de Jong, Paul C and Jonker, Marianne A and Vos, Allert H and Grootjans, Willem and de Groot, Johannes W. B and Mulder, Sasja F and Aarntzen, Erik H. J. G and Gerritsen, Winald R and van Herpen, Carla M. L and van Erp, Nielka P
Targeted Oncology, ISSN 1776-2596, 10/2018, Volume 13, Issue 5, pp. 641 - 648
MAMMALIAN TARGET | PLUS EXEMESTANE | SOLID TUMORS | EFFICACY | MTOR INHIBITOR EVEROLIMUS | SAFETY | PHASE-I | ENDOCRINE MONOTHERAPY | PET | CHEMOTHERAPY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Everolimus plus Exemestane in Postmenopausal Metastatic Breast Cancer Patients
by Yamamoto, Daigo and Tsubota, Yu and Sueoka, Noriko and Yamamoto, Chizuko and Kon, Masanori
Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 10/2015, Volume 42, Issue 10, pp. 1319 - 1321
Everolimus plus exemestane | Breast cancer
Journal Article
Details down arrow
8. Full Text Exemestane for Breast Cancer Prevention: A Feasible Strategy?
by Per E. Lønning
Clinical Cancer Research, ISSN 1078-0432, 01/2005, Volume 11, Issue 2, pp. 918s - 924S
Third-generation aromatase inhibitors and inactivators have been successfully implemented in therapy of metastatic breast cancer, and three large phase III... 
breast cancer | exemestane | inactivator | aromatase | prevention | SURGICAL ADJUVANT BREAST | PERIPHERAL AROMATIZATION | ONCOLOGY | RANDOMIZED-TRIAL | RISK | ESTROGEN PLUS PROGESTIN | POSTMENOPAUSAL WOMEN | 1ST-LINE THERAPY | STEROIDAL AROMATASE INHIBITOR | SEX-HORMONE LEVELS | TAMOXIFEN THERAPY | Humans | Risk Factors | Postmenopause | Female | Androstadienes - therapeutic use | Clinical Trials as Topic | Aromatase Inhibitors - therapeutic use | Breast Neoplasms - prevention & control
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
by Cardoso, F and Costa, A and Norton, L and Senkus, E and Aapro, M and André, F and Barrios, C.H and Bergh, J and Biganzoli, L and Blackwell, K.L and Cardoso, M.J and Cufer, T and El Saghir, N and Fallowfield, L and Fenech, D and Francis, P and Gelmon, K and Giordano, S.H and Gligorov, J and Goldhirsch, A and Harbeck, N and Houssami, N and Hudis, C and Kaufman, B and Krop, I and Kyriakides, S and Lin, U.N and Mayer, M and Merjaver, S.D and Nordström, E.B and Pagani, O and Partridge, A and Penault-Llorca, F and Piccart, M.J and Rugo, H and Sledge, G and Thomssen, C and Van't Veer, L and Vorobiof, D and Vrieling, C and West, N and Xu, B and Winer, E
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, ISSN 0923-7534, 10/2014, Volume 25, Issue 10, pp. 1871 - 1888
PHASE-III TRIAL | EVEROLIMUS PLUS EXEMESTANE | MIDDLE-INCOME COUNTRIES | ONCOLOGY | ISOLATED LOCOREGIONAL RECURRENCE | PRIMARY TUMOR | PATIENT NAVIGATION | DOUBLE-BLIND | POSTMENOPAUSAL WOMEN | 1ST-LINE THERAPY | FIRST-LINE THERAPY | Special
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text The therapeutic potential of mTOR inhibitors in breast cancer
by Steelman, Linda S and Martelli, Alberto M and Cocco, Lucio and Libra, Massimo and Nicoletti, Ferdinando and Abrams, Stephen L and McCubrey, James A
British Journal of Clinical Pharmacology, ISSN 0306-5251, 11/2016, Volume 82, Issue 5, pp. 1189 - 1212
Rapamycin and modified rapamycins (rapalogs) have been used to prevent allograft rejection after organ transplant for over 15 years. The mechanistic target of... 
everolimus | exemestane | drug resistance | endocrine resistance | metastasis | rapamycin | Endocrine resistance | Rapamycin | Metastasis | Drug resistance | Exemestane | Everolimus | MAMMALIAN TARGET | SIGNALING PATHWAYS | TRASTUZUMAB RESISTANCE | EVEROLIMUS PLUS EXEMESTANE | GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | NEOADJUVANT CHEMOTHERAPY | PI3K PATHWAY | PHARMACOLOGY & PHARMACY | POSTMENOPAUSAL WOMEN | NF-KAPPA-B | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Models, Biological | Protein Kinase Inhibitors - therapeutic use | Humans | Female | Mechanistic Target of Rapamycin Complex 1 - antagonists & inhibitors | Aromatase Inhibitors - therapeutic use | Breast Neoplasms - drug therapy | Breast cancer | Health aspects | Drug approval | Review‐themed Issue
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline
by Rugo, Hope S and Rumble, R. Bryan and Macrae, Erin and Barton, Debra L and Connolly, Hannah Klein and Dickler, Maura N and Fallowfield, Lesley and Fowble, Barbara and Ingle, James N and Jahanzeb, Mohammad and Johnston, Stephen R. D and Korde, Larissa A and Khatcheressian, James L and Mehta, Rita S and Muss, Hyman B and Burstein, Harold J
Journal of Clinical Oncology, ISSN 0732-183X, 09/2016, Volume 34, Issue 25, pp. 3069 - 3103
Purpose To develop recommendations about endocrine therapy for women with hormone receptor (HR) -positive metastatic breast cancer (MBC). Methods The American... 
PHASE-III TRIAL | EVEROLIMUS PLUS EXEMESTANE | GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | FULVESTRANT 500 MG | ONCOLOGY | PROGRESSION-FREE SURVIVAL | DOUBLE-BLIND | POSTMENOPAUSAL JAPANESE WOMEN | PLACEBO-CONTROLLED TRIAL | FIRST-LINE THERAPY | Female | Receptors, Estrogen - metabolism | Breast Neoplasms - drug therapy | Humans | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Exemestane and Chemotherapy as First-line Treatment of Metastatic Breast Cancer: Results of a Phase II Study
by de la Haba-Rodriguez, Juan and Mancha, Rosario González and Manga, Gumersindo Pérez and Aguilar, Enrique Aranda and Baena Cañada, José Manuel and Rovira, Pedro Sánchez and Conejo, Emilio Alba
Clinical Breast Cancer, ISSN 1526-8209, 2010, Volume 10, Issue 4, pp. 313 - 317
Abstract Background Metastatic breast cancer remains largely incurable. Strategies involving the combination of the selective estrogen receptor modulator... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Pulmonary embolism | Anthracyline | Pneumonia | Advanced breast cancer | HER2 | Trastuzumab | DRUG-THERAPY | TAMOXIFEN | RANDOMIZED-TRIAL | ADJUVANT THERAPY | HORMONAL TREATMENT | ENDOCRINE TREATMENT | PLUS CAPECITABINE | ONCOGENE | ONCOLOGY | POSTMENOPAUSAL WOMEN | AROMATASE INHIBITORS | Cyclophosphamide - administration & dosage | Humans | Middle Aged | Kaplan-Meier Estimate | Treatment Outcome | Epirubicin - administration & dosage | Breast Neoplasms - drug therapy | Disease-Free Survival | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Postmenopause | Breast Neoplasms - mortality | Female | Aged | Androstadienes - therapeutic use | Aromatase Inhibitors - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer
by Montagnani, A and Gonnelli, S and Cadirni, A and Caffarelli, C and Del Santo, K and Pieropan, C and Campagna, M.S and Montomoli, M and Petrioli, R and Nuti, R
European Journal of Internal Medicine, ISSN 0953-6205, 2008, Volume 19, Issue 8, pp. 592 - 597
Abstract Background The third-generation aromatase inhibitor exemestane represents a new development in the treatment of estrogen-positive breast cancer. The... 
Internal Medicine | Lipid profile | Breast cancer | Body composition | Cardiovascular risk | Aromatase inhibitors | PREVENTION | RANDOMIZED-TRIAL | ENDOCRINE THERAPY | ANASTROZOLE | MEDICINE, GENERAL & INTERNAL | PROFILE | PLASMA-LIPIDS | CARDIOVASCULAR-DISEASE | CORONARY-HEART-DISEASE | ESTROGEN PLUS PROGESTIN | Body Composition | Single-Blind Method | Postmenopause - blood | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Breast Neoplasms - metabolism | Estrogen Receptor Modulators - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Lipids - blood | Cholesterol, LDL - blood | Female | Chemotherapy, Adjuvant | Aromatase Inhibitors - therapeutic use | Cholesterol, HDL - drug effects | Cholesterol, LDL - drug effects | Treatment Outcome | Biomarkers - blood | Breast Neoplasms - drug therapy | Tamoxifen - therapeutic use | Triglycerides - blood | Cholesterol, HDL - blood | Aged | Androstadienes - therapeutic use | Cohort Studies | Antimitotic agents | Women | Care and treatment | Adjuvant treatment | Postmenopausal women | Antineoplastic agents | Tamoxifen | Cancer | Estrogen
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text C-6 alpha- vs C-7 alpha-Substituted Steroidal Aromatase Inhibitors: Which Is Better? Synthesis, Biochemical Evaluation, Docking Studies, and Structure-Activity Relationships
by Roleira, FMF and Varela, C and Amaral, C and Costa, SC and Correia-da-Silva, G and Moraca, F and Costa, G and Alcaro, S and Teixeira, NAA and da Silva, EJT
JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0022-2623, 04/2019, Volume 62, Issue 7, pp. 3636 - 3657
C-6 alpha and C-7 alpha androstanes were studied to disclose which position among them is more convenient to functionalize to reach superior aromatase... 
EVEROLIMUS PLUS EXEMESTANE | CELLS | DESIGN | CHEMISTRY, MEDICINAL | ADVANCED BREAST-CANCER | BIOLOGICAL-ACTIVITY | X-RAY | LIGAND | BINDING-SITES | ESTROGEN-RECEPTOR | HORMONES
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
by Finn, Richard S, MD and Crown, John P, Prof and Lang, Istvan, MD and Boer, Katalin, MD and Bondarenko, Igor M, Prof and Kulyk, Sergey O, MD and Ettl, Johannes, MD and Patel, Ravindranath, MD and Pinter, Tamas, MD and Schmidt, Marcus, MD and Shparyk, Yaroslav, MD and Thummala, Anu R, MD and Voytko, Nataliya L, MD and Fowst, Camilla, MD and Huang, Xin, PhD and Kim, Sindy T, BS and Randolph, Sophia, MD and Slamon, Dennis J, Prof
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 25 - 35
Summary Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EXEMESTANE | ONCOLOGY | CELL-CYCLE | POSTMENOPAUSAL WOMEN | HER2 | PLUS | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Triazoles - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Molecular Targeted Therapy | North America | Nitriles - administration & dosage | Breast Neoplasms - enzymology | Time Factors | Postmenopause | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Republic of Korea | Aromatase Inhibitors - administration & dosage | Pyridines - administration & dosage | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Europe | Proportional Hazards Models | Cyclin-Dependent Kinase Inhibitor p16 - genetics | Treatment Outcome | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Cyclin D1 - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | South Africa | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Care and treatment | Oncology, Experimental | Estrogen | Breast cancer | Research | Antineoplastic agents | Phosphotransferases | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights